QI
TEVA icon

QS Investors’s Teva Pharmaceuticals TEVA Stock Holding History

QS Investors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-54,280
Closed -$852K – 1675
2019
Q1 		$852K Sell
54,280
-16,410
-23% -$289K 0.01% 855
2018
Q4 		$1.09M Buy
70,690
+67,280
+1,973% +$1.38M 0.01% 743
2018
Q3 		$73K Sell
3,410
-1,000
-23% -$23.2K ﹤0.01% 1447
2018
Q2 		$107K Sell
4,410
-4,800
-52% -$97.9K ﹤0.01% 1392
2018
Q1 		$157K Sell
9,210
-11,880
-56% -$232K ﹤0.01% 1261
2017
Q4 		$400K Sell
21,090
-1,564
-7% -$23.5K ﹤0.01% 999
2017
Q3 		$399K Sell
22,654
-67,647
-75% -$1.52M ﹤0.01% 1017
2017
Q2 		$3M Buy
90,301
+7,543
+9% +$233K 0.03% 462
2017
Q1 		$2.66M Buy
82,758
+1,097
+1% +$37.4K 0.02% 518
2016
Q4 		$2.96M Buy
81,661
+6,680
+9% +$267K 0.02% 501
2016
Q3 		$3.45M Buy
74,981
+9,014
+14% +$470K 0.03% 495
2016
Q2 		$3.31M Sell
65,967
-140,974
-68% -$7.5M 0.03% 513
2016
Q1 		$11.1M Buy
206,941
+513
+0.2% +$30.1K 0.11% 184
2015
Q4 		$13.6M Sell
206,428
-2,038
-1% -$126K 0.13% 143
2015
Q3 		$11.8M Sell
208,466
-5,178
-2% -$336K 0.12% 159
2015
Q2 		$12.6M Buy
213,644
+18,577
+10% +$1.15M 0.16% 150
2015
Q1 		$12.2M Buy
195,067
+45,933
+31% +$2.67M 0.14% 175
2014
Q4 		$8.58M Buy
149,134
+131,593
+750% +$7.33M 0.1% 235
2014
Q3 		$943K Sell
17,541
-25,020
-59% -$1.33M 0.03% 361
2014
Q2 		$2.23M Buy
42,561
+38,426
+929% +$1.96M 0.06% 250
2014
Q1 		$218K Sell
4,135
-865
-17% -$40K 0.01% 575
2013
Q4 		$200K Buy
+5,000
New +$197K 0.01% 567

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

QS Investors's TEVA Position: Q2 2019 in Review

QS Investors sold out of Teva Pharmaceuticals (TEVA) in Q2 2019, closing a stake of 54,280 shares — an estimated $852K sold.

QS Investors first reported a position in TEVA in Q4 2013 and held it in 22 quarters. The position peaked at $13.6M in Q4 2015. 452 funds tracked by Wall St. Rank hold TEVA as of Q2 2019.

  • QS Investors reported no remaining Teva Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • QS Investors sold 54,280 Teva Pharmaceuticals shares in Q2 2019, an estimated $852K.
  • QS Investors first reported a position in Teva Pharmaceuticals in Q4 2013 and held it in 22 quarters.
  • QS Investors's Teva Pharmaceuticals position peaked at $13.6M in Q4 2015.
  • 452 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2019.

Based on QS Investors's 13F filing for Q2 2019, filed 14 Aug 2019.